

# Development of SIRT7 inhibitors for the treatment of unresectable hepatocellular carcinoma

Korea Research Institute of Chemical Technology



ONCOLOGY	Lead
Product Type	Small Molecule
Indication	Hepatocellular Carcinoma
Target	SIRT7
MoA(Mechanism of Action)	SIRT7 inhibition - DDX3X acetylation – inhibition of ERK1/2 phosphorylation
Competitiveness	Fist in class - Validation of efficacy for unresectable hepatocellular carcinoma and re-sensitization of sorafenib-resistant hepatocellular carcinoma model
Development Stage	Lead
Route of Administration	Enteral-Oral